CDD-2807

• Description :

  CDD-2807 is an inhibitor for serine/threonine kinase 33 (STK33) with IC50 of 9.2 nM. CDD-2807 exhibits no significant toxicity in mice and can cross the blood-testis barrier without accumulating in the brain. CDD-2807 induces a reversible contraceptive effect and has potential for the development of the male contraceptive[1].

• UNSPSC :

  12352005

• Target :

  CDK; RET; STK33

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/cdd-2807.html

• Purity :

  99.52

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC2=C(NN=C2C#CC3=CC=CC=C3C4=CC=CC=C4)C=C1)N5CC6(CNCCC6)C5

• Molecular Formula :

  C29H26N4O

• Molecular Weight :

  446.54

• References & Citations :

  [1]Ku AF, et al., Reversible male contraception by targeted inhibition of serine/threonine kinase 33. Science. 2024 May 24;384 (6698) :885-890.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CLK

• CAS Number :

  [3086536-23-1]